Early access
Sign in
CompletedPhase 2

Pilot Study on BP1.4979 Effect on Binge Eating Disorders

Key facts

Who runs it
Bioprojet
Where
France and Spain13 sites in 2 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
67 people enrolled
Started
7 Mar 2022
Ended
21 Aug 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BP1.4979 active drug
  • Placebo
Record updated
25 November 2025

Who can take part

Age
18 years to 65 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to beginning any protocol required procedures
  • Female aged between 18 and 65 years, inclusive
  • Diagnosis of BED according to DSM-5 criteria
  • BMI < 50 kg/m2

Who cannot take part

  • Patient who is pregnant, lactating, or of childbearing potential who is not using adequate contraceptive measures. The following are considered adequate methods of birth control: 1. intrauterine device (IUD); 2. barrier protection; 3. contraceptive implantation system; 4. oral contraceptive pills; 5. surgically sterile patient; and 6. abstinence. All participants should have a negative pregnancy test prior to randomization
  • Ongoing alcohol or tobacco addiction treatment (except Nicotine Replacement Therapy [NRT] with at least one-month stable dose prior to screening visit)
  • History of bariatric surgery
  • Current diagnosis of bulimia nervosa or anorexia nervosa

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This pilot study is to assess the efficacy and safety of BP1.4979 15 mg BID in female patients with moderate to severe binge eating disorder (BED), as defined according to DSM-5 guidelines.

The 2 groups in the trial

  • BP1.4979Treatment being tested

    15 mg BID active treatment

    Treatment: BP1.4979 active drug

  • PlaceboPlacebo, for comparison

    matching placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Double-blind, Placebo-controlled Pilot Trial of BP1.4979 for the Treatment of Binge Eating Disorder
Record updated
25 November 2025